Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Investigator: Jorge Darcourt, MD

Study Coordinator: Syed Muhammad Saad

Status: Enrolling Number: NCT03547973

Phone: 281.276.5263

Protocol Number: Pro00021842


This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.
More to Explore
Live Chat Available